Biolinq Inc., the San Diego-based medical device company, announced today that the company has successfully demonstrated the feasibility of a minimally invasive continuous glucose monitor (CGM), showing a high correlation between dermal interstitial glucose and venous blood glucose.
| SAN DIEGO, June 15, 2020 /PRNewswire/ --Biolinq Inc., the San Diego-based medical device company, announced today that the company has successfully demonstrated the feasibility of a minimally invasive continuous glucose monitor (CGM), showing a high correlation between dermal interstitial glucose and venous blood glucose. The results of the firm’s two most recent clinical studies were presented at the American Diabetes Association 80th Scientific Sessions and shows the feasibility of a microneedle CGM system. The current Biolinq CGM is an investigational device available for use only in approved clinical studies. The data from the study was presented by company CEO, Jared Tangney, PhD, in the Late-Breaking Poster session, on Saturday, June 13th as poster 69-LB “A Wearable Microneedle Array Sensor Shows High Correlation between Dermal Glucose and Venous Blood Glucose.” “The team at Biolinq has been working for many years to establish the benefits of dermal sensing for CGM. We are thrilled to share the promising feasibility data from our recent studies. We believe that this positive data is a major step towards making this product a reality for people with diabetes.” -Jared Tangney, PhD, CEO, Biolinq Inc. Biolinq’s novel platform uses dozens of miniature sensors, much less than 1 mm in length, to continuously measure blood glucose in the outer layer of the skin (the dermis). The product has no introducer needle resulting in a pain-free application of the sensors and can be worn almost anywhere on the body. The company is targeting the clearance of the device through the FDA iCGM pathway. The Late Breaking Poster shows the high degree of correlation between the Biolinq sensor raw data and venous blood glucose with little to no lag time - something patients and industry experts believe has the potential to deliver better outcomes to those living with type 1 and type 2 diabetes. Phase 1 of the study consisted of 5 subjects without diabetes and 10 subjects with diabetes who wore the Biolinq sensor for two days. In the second phase, 10 subjects with diabetes wore the Biolinq sensor for seven days. Data from the Biolinq devices was compared to venous blood reference measurements. Mark Christiansen, MD (Co-Medical Director, Diablo Clinical Research), the Principal Investigator and an experienced researcher in the field, said the following: “I am very encouraged by Biolinq’s data, especially the high correlation between the raw sensor signal and the blood glucose and the absence of the venous to interstitial fluid glucose lag time.” Further studies of the Biolinq CGM are planned for later this year. About Biolinq Inc. Media Contact: Link to Abstract: https://bit.ly/biolinq
SOURCE Biolinq Inc. |
View original content to download multimedia:
